atopic%20dermatitis%20(pediatric)
ATOPIC DERMATITIS (PEDIATRIC)
Atopic dermatitis is a familial, chronic relapsing inflammatory skin disease characterized by intense itching, dry skin, with inflammation and exudation that commonly presents during early infancy and childhood, but can persist or start in adulthood.
It is also referred to as atopic eczema.
It is one of the most common skin diseases afflicting both adults and children.

Introduction

  • One of the most common skin diseases afflicting both adults & children
  • Infant’s skin has a developing epidermal barrier & would only fully mature at least at 1st year of age thus their skin absorb more water & lose excess water faster than adult skin
    • This skin characteristic makes them susceptible to irritation & infections

Definition

  • A familial, chronic relapsing inflammatory skin disease characterized by intense itching, dry skin, w/ inflammation & exudation that commonly presents during early infancy & childhood, but can persist or start in adulthood
  • Also referred to as “atopic eczema”

Etiology

  • Common causes include allergens such as food, soaps, detergents, inhalant allergens & skin infections

Pathophysiology

  • Heredity (80% in monozygous twins, 20% in heterozygous twins)
  • Increased immunoglobulin E (IgE) production
  • Lack of skin barrier producing dry skin due to abnormalities in lipid metabolism & protein formation
  • Susceptibility to infections caused by Staphylococcus aureus/epidermidisMalassezia furfur

Signs and Symptoms

Infants <2 years usually present w/:

  • Signs of inflammation usually develop during the 3rd month of life
  • Patient commonly presents w/ red, scaling, dry areas
    • Usually found on the facial cheeks &/or chin
    • Lip licking may result in scaling, oozing & crusting on the lips & perioral skin, eventually leading to secondary infections
    • Perioral & perinasal sparing can be characteristic & patient may present w/ no lesions in these areas
  • Continued scratching or washing will create scaling, oozing, red plaques on cheeks
    •  Infant may be restless or agitated during sleep
  •  A small number of infants may present w/ generalized eruptions
    •  Papules, redness, scaling & lichenification
    •  Diaper area is usually not affected

Children 2-12 years usually present w/:

  • Inflammation in the flexural areas
    • Eg neck, wrists, ankles, antecubital fossae
  • Rash may be contained to 1 or 2 areas
    •  May progress to involve more areas eg neck, antecubital & popliteal fossae, wrists & ankles
  •  Papules that quickly change to plaques then lichenified when scratched
  •  Constant scratching may lead to areas of hypo- or hyperpigmentation

Adolescents ≥12 years usually present w/:

  • Resurgence of inflammation that recurs near puberty
  • Pattern of inflammation is the same as in a child 2-12 years
  • Dry, scaling, erythematous papules & plaques
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS JPOG - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 31 Dec 2019
Adding the neuraminidase inhibitor oseltamivir to usual care speeds up recovery from influenza-like illness by a day compared with usual care alone, with even greater benefits seen in older, sicker patients with comorbidities, according to the ALIC4E study.
Roshini Claire Anthony, 3 days ago

The presence of pulmonary arterial hypertension (PAH) in individuals with systemic sclerosis is associated with an increased mortality risk, a study from Singapore showed.

23 Dec 2019
At a Menarini-sponsored symposium held during the Asian Pacific Society Congress, renowned cardiologist Prof John Camm provided the latest evidence for chronic stable angina with or without concomitant diseases, with a special focus on the antianginal agent ranolazine and combination therapies. The event was chaired and moderated by Dr Dante Morales from the University of the Philippines College of Medicine.
Stephen Padilla, 6 days ago
Brodalumab has exhibited long-term efficacy and consistent safety profile for more than 2 years in the treatment of patients with psoriasis, results of the phase III AMAGINE-2 trial show.